chr11-77174817-G-A
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PP3PM2_Supporting
This summary comes from the ClinGen Evidence Repository: The c.1997G>A (p.Arg666Gln) variant in MYO7A is present in 10/42046 (0.012% CI 95%) of African alleles in gnomAD v3, which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Usher syndrome (PM2_Supporting). This variant has been detected in 1 proband with Usher syndrome, however, they carried another VUS with phase unknown (PM3_Supporting not met; ClinVar ID: 196099; PMIDs: 27460420, 31479088). The REVEL computational prediction analysis tool produced a score of 0.841, which is above the threshold necessary to apply PP3. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting, PP3. LINK:https://erepo.genome.network/evrepo/ui/classification/CA6197659/MONDO:0019501/005
Frequency
Consequence
NM_000260.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYO7A | NM_000260.4 | c.1997G>A | p.Arg666Gln | missense_variant | 17/49 | ENST00000409709.9 | NP_000251.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO7A | ENST00000409709.9 | c.1997G>A | p.Arg666Gln | missense_variant | 17/49 | 1 | NM_000260.4 | ENSP00000386331 | ||
MYO7A | ENST00000458637.6 | c.1997G>A | p.Arg666Gln | missense_variant | 17/49 | 1 | ENSP00000392185 | P1 | ||
MYO7A | ENST00000409619.6 | c.1964G>A | p.Arg655Gln | missense_variant | 18/50 | 1 | ENSP00000386635 | |||
MYO7A | ENST00000409893.6 | c.62G>A | p.Arg21Gln | missense_variant | 1/11 | 5 | ENSP00000386689 |
Frequencies
GnomAD3 genomes AF: 0.0000854 AC: 13AN: 152244Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000203 AC: 5AN: 246412Hom.: 0 AF XY: 0.0000149 AC XY: 2AN XY: 134202
GnomAD4 exome AF: 0.00000890 AC: 13AN: 1460678Hom.: 0 Cov.: 34 AF XY: 0.00000551 AC XY: 4AN XY: 726516
GnomAD4 genome AF: 0.0000853 AC: 13AN: 152362Hom.: 0 Cov.: 33 AF XY: 0.0000939 AC XY: 7AN XY: 74508
ClinVar
Submissions by phenotype
Usher syndrome type 1 Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | Apr 21, 2023 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center | Mar 25, 2024 | - - |
Usher syndrome Uncertain:1
Uncertain significance, reviewed by expert panel | curation | ClinGen Hearing Loss Variant Curation Expert Panel | May 20, 2020 | The c.1997G>A (p.Arg666Gln) variant in MYO7A is present in 10/42046 (0.012% CI 95%) of African alleles in gnomAD v3, which is a low enough frequency to award PM2_Supporting based on the thresholds defined by the ClinGen Hearing Loss Expert Panel for autosomal recessive Usher syndrome (PM2_Supporting). This variant has been detected in 1 proband with Usher syndrome, however, they carried another VUS with phase unknown (PM3_Supporting not met; ClinVar ID: 196099; PMIDs: 27460420, 31479088). The REVEL computational prediction analysis tool produced a score of 0.841, which is above the threshold necessary to apply PP3. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel: PM2_Supporting, PP3. - |
Usher syndrome type 1;C1838701:Autosomal recessive nonsyndromic hearing loss 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Feb 28, 2018 | - - |
Usher syndrome type 1B Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jan 16, 2020 | - - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 13, 2022 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 666 of the MYO7A protein (p.Arg666Gln). This variant is present in population databases (rs782396605, gnomAD 0.01%). This missense change has been observed in individual(s) with Usher syndrome, deafness (PMID: 27344577, 27460420, 31479088, 33297549). ClinVar contains an entry for this variant (Variation ID: 556881). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on MYO7A protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at